succinobucol has been researched along with Coronary Artery Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunsch, C; Malinin, A; Qiu, FH; Scott, R; Serebruany, V; Xu, XC | 1 |
| Edwards, D; Kunsch, C; Medford, RM; Meng, CQ; Sundell, CL; Wasserman, MA | 1 |
| Grégoire, J; L'Allier, PL; Lavoie, MA; Tardif, JC | 2 |
| Anderson, TJ; Bertrand, OF; Brennan, ML; Grégoire, J; Guertin, MC; Hazen, SL; Ibrahim, R; L'Allier, PL; LeMay, M; Lespérance, J; Reeves, F; Schampaert, E; Scott, R; Tardif, JC; Title, LM | 1 |
| Eisert, C; Malinin, A; Ong, S; Serebruany, VL | 1 |
| Douglas, JS | 1 |
| Senior, K | 1 |
5 review(s) available for succinobucol and Coronary Artery Disease
| Article | Year |
|---|---|
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Topics: Antioxidants; Arteriosclerosis; Cardiovascular System; Coronary Artery Disease; Humans; Probucol; Signal Transduction | 2003 |
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; ortho-Aminobenzoates; Oxidative Stress; Probucol; Sirolimus; Vitamins | 2003 |
Vascular protectants for the treatment of atherosclerosis.
Topics: Antioxidants; Coronary Artery Disease; Humans; Probucol; Protective Agents; Randomized Controlled Trials as Topic; Research Design | 2003 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosis; Cytokines; Disease Progression; Humans; Hypolipidemic Agents; Oxidative Stress; Platelet Aggregation Inhibitors; Probucol; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2007 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |
2 trial(s) available for succinobucol and Coronary Artery Disease
| Article | Year |
|---|---|
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Topics: Adolescent; Adult; Aged; Biomarkers; Cells, Cultured; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Lipoproteins; Male; Middle Aged; Probucol; Risk Factors; Thromboxanes; Vascular Diseases; Young Adult | 2009 |
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Topics: Aged; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peroxidase; Probucol; Treatment Outcome; Ultrasonography, Interventional | 2008 |
1 other study(ies) available for succinobucol and Coronary Artery Disease
| Article | Year |
|---|---|
Drug reverses coronary atherosclerosis.
Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Vessels; Humans; Probucol | 2002 |